lacosamide · Ucb Inc · NDA 022253, 022254, 022255

Vimpat

Earliest generic entry, as listed · earliest of 6 marketed strengths

Open now

No unexpired patents or exclusivities are listed for this product.

Listed patents · 0 unexpired

No unexpired patents listed.

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

25 Oct 2026Generic approved · 022255-00115 Jun 2026
25 Oct 2026Generic approved · 022255-00129 Jan 2026
25 Oct 2026Generic approved · 022255-00121 May 2026
25 Oct 2026Generic approved · 022254-00121 Jan 2026

Products covered · 6

NDA · product	Form	Strength	Approved	Listed expiry
022253 · 001 · RLD	tablet, oral	50MG	28 Oct 2008	open
022253 · 002 · RLD	tablet, oral	100MG	28 Oct 2008	open
022253 · 003 · RLD	tablet, oral	150MG	28 Oct 2008	open
022253 · 004 · RLD	tablet, oral	200MG	28 Oct 2008	open
022254 · 001 · RLD	solution, intravenous	200MG/20ML (10MG/ML)	28 Oct 2008	open
022255 · 001 · RLD	solution, oral	10MG/ML	20 Apr 2010	open

Expired or delisted (1)

D-188 · 28 Apr 2026